NCT06797011View on ClinicalTrials.gov

Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 25, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Drug Induced Liver InjuryChronic Liver Disease

Interventions

BIOLOGICAL

High volume Plasma Exchange

High volume Plasma Exchange with minimum 3 sessions on alternate days

OTHER

Standard Medical Treatment

Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors

lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06797011 - Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease | Biotech Hunter | Biotech Hunter